395 related articles for article (PubMed ID: 27784794)
41. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1.
O'Brien PJ; Prevost N; Molino M; Hollinger MK; Woolkalis MJ; Woulfe DS; Brass LF
J Biol Chem; 2000 May; 275(18):13502-9. PubMed ID: 10788464
[TBL] [Abstract][Full Text] [Related]
42. PAR4-Mediated PI3K/Akt and RhoA/ROCK Signaling Pathways Are Essential for Thrombin-Induced Morphological Changes in MEG-01 Cells.
Heo Y; Jeon H; Namkung W
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054966
[TBL] [Abstract][Full Text] [Related]
43. Protease-activated receptors differentially regulate human platelet activation through a phosphatidic acid-dependent pathway.
Holinstat M; Voss B; Bilodeau ML; Hamm HE
Mol Pharmacol; 2007 Mar; 71(3):686-94. PubMed ID: 17151288
[TBL] [Abstract][Full Text] [Related]
44. PKC inhibition markedly enhances Ca2+ signaling and phosphatidylserine exposure downstream of protease-activated receptor-1 but not protease-activated receptor-4 in human platelets.
Harper MT; Poole AW
J Thromb Haemost; 2011 Aug; 9(8):1599-607. PubMed ID: 21649850
[TBL] [Abstract][Full Text] [Related]
45. Macrophage Migration Inhibitory Factor Mediates PAR-Induced Bladder Pain.
Kouzoukas DE; Meyer-Siegler KL; Ma F; Westlund KN; Hunt DE; Vera PL
PLoS One; 2015; 10(5):e0127628. PubMed ID: 26020638
[TBL] [Abstract][Full Text] [Related]
46. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets.
Ma L; Perini R; McKnight W; Dicay M; Klein A; Hollenberg MD; Wallace JL
Proc Natl Acad Sci U S A; 2005 Jan; 102(1):216-20. PubMed ID: 15615851
[TBL] [Abstract][Full Text] [Related]
47. Inflammatory mediators modulate thrombin and cathepsin-G signaling in human bronchial fibroblasts by inducing expression of proteinase-activated receptor-4.
Ramachandran R; Sadofsky LR; Xiao Y; Botham A; Cowen M; Morice AH; Compton SJ
Am J Physiol Lung Cell Mol Physiol; 2007 Mar; 292(3):L788-98. PubMed ID: 17142351
[TBL] [Abstract][Full Text] [Related]
48. Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage.
Jacques SL; Kuliopulos A
Biochem J; 2003 Dec; 376(Pt 3):733-40. PubMed ID: 13678420
[TBL] [Abstract][Full Text] [Related]
49. Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca
Morikawa Y; Kato H; Kashiwagi H; Nishiura N; Akuta K; Honda S; Kanakura Y; Tomiyama Y
Thromb Res; 2018 Feb; 162():44-52. PubMed ID: 29289806
[TBL] [Abstract][Full Text] [Related]
50. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
Wong PC; Seiffert D; Bird JE; Watson CA; Bostwick JS; Giancarli M; Allegretto N; Hua J; Harden D; Guay J; Callejo M; Miller MM; Lawrence RM; Banville J; Guy J; Maxwell BD; Priestley ES; Marinier A; Wexler RR; Bouvier M; Gordon DA; Schumacher WA; Yang J
Sci Transl Med; 2017 Jan; 9(371):. PubMed ID: 28053157
[TBL] [Abstract][Full Text] [Related]
51. Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site.
Nieman MT; Schmaier AH
Biochemistry; 2007 Jul; 46(29):8603-10. PubMed ID: 17595115
[TBL] [Abstract][Full Text] [Related]
52. Protease-activated receptor 4 uses anionic residues to interact with alpha-thrombin in the absence or presence of protease-activated receptor 1.
Nieman MT
Biochemistry; 2008 Dec; 47(50):13279-86. PubMed ID: 19053259
[TBL] [Abstract][Full Text] [Related]
53. A cluster of aspartic residues in the extracellular loop II of PAR 4 is important for thrombin interaction and activation of platelets.
Sánchez Centellas D; Gudlur S; Vicente-Carrillo A; Ramström S; Lindahl TL
Thromb Res; 2017 Jun; 154():84-92. PubMed ID: 28448853
[TBL] [Abstract][Full Text] [Related]
54. Platelet Lipidomic Profiling: Novel Insight into Cytosolic Phospholipase A2α Activity and Its Role in Human Platelet Activation.
Duvernay MT; Matafonov A; Lindsley CW; Hamm HE
Biochemistry; 2015 Sep; 54(36):5578-88. PubMed ID: 26295742
[TBL] [Abstract][Full Text] [Related]
55. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation.
Wu CC; Wu SY; Liao CY; Teng CM; Wu YC; Kuo SC
Br J Pharmacol; 2010 Oct; 161(3):643-58. PubMed ID: 20880402
[TBL] [Abstract][Full Text] [Related]
56. Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog.
Lin YC; Ko YC; Hung SC; Lin YT; Lee JH; Tsai JY; Kung PH; Tsai MC; Chen YF; Wu CC
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):694-703. PubMed ID: 30727756
[TBL] [Abstract][Full Text] [Related]
57. Differential Effects of Platelets Selectively Activated by Protease-Activated Receptors on Meniscal Cells.
Xu H; Zou X; Xia P; Aboudi MAK; Chen R; Huang H
Am J Sports Med; 2020 Jan; 48(1):197-209. PubMed ID: 31765237
[TBL] [Abstract][Full Text] [Related]
58. Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets.
Arachiche A; de la Fuente M; Nieman MT
PLoS One; 2014; 9(5):e97724. PubMed ID: 24830314
[TBL] [Abstract][Full Text] [Related]
59. Both the high affinity thrombin receptor (GPIb-IX-V) and GPIIb/IIIa are implicated in expression of thrombin-induced platelet procoagulant activity.
Dicker IB; Pedicord DL; Seiffert DA; Jamieson GA; Greco NJ
Thromb Haemost; 2001 Oct; 86(4):1065-9. PubMed ID: 11686325
[TBL] [Abstract][Full Text] [Related]
60. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.
Hawes BE; Zhai Y; Hesk D; Wirth M; Wei H; Chintala M; Seiffert D
Eur J Pharmacol; 2015 Sep; 762():221-8. PubMed ID: 26022529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
